Saturday, June 27, 2020 12:17:30 PM
I wouldn't put it past the carter team to simply file 1 expert report after another that simply up the price by a fraction of a margin to further solidify the case
(affirming/validating a previous post inferring this is all a "game of winning" with lawyers)
I tried to scrutinize Teece versus Tyler's background for variables/differences but they are both WELL ESTABLISHED with various arenas of proficiency
what stood out re: Tyler's CV for PTC was ~ "competition economics" &
"the relationship between price and speed using regression analyses"..these assertions inevitably will be the bottom line to what our PPS will be worth when all is said & done
re: previous post ~ b4 someone points out the word "biosimilar" ..feel free to amend to "similar" for our IT status infringement
re: Intellectual Property and Damages
Reasonable royalty for patent infringement involving manufacturing process and method of treatment for a biosimilar product
(affirming/validating a previous post inferring this is all a "game of winning" with lawyers)
I tried to scrutinize Teece versus Tyler's background for variables/differences but they are both WELL ESTABLISHED with various arenas of proficiency
what stood out re: Tyler's CV for PTC was ~ "competition economics" &
"the relationship between price and speed using regression analyses"..these assertions inevitably will be the bottom line to what our PPS will be worth when all is said & done
re: previous post ~ b4 someone points out the word "biosimilar" ..feel free to amend to "similar" for our IT status infringement
re: Intellectual Property and Damages
Reasonable royalty for patent infringement involving manufacturing process and method of treatment for a biosimilar product
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
